SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BBNX reported Third Quarter 2026 results. The price and volatility reaction is pending.
BBNXearnings

Earnings reactions, page 11

Beta Bionics, Inc. (BBNX) Q3 FY2026 earnings

October 28, 2026 · SharpeIQ Research Desk

Reported results

  • Net sales were $35.5 million for the third quarter of 2026.
  • Durable Medical Equipment (DME) channel net sales were $21.9 million.
  • Pharmacy Benefit Plan (PBP) channel net sales were $13.6 million.
  • Gross margin was 57.3% for the third quarter of 2026.
  • Loss from operations was $26.6 million for the third quarter of 2026.
  • Adjusted EBITDA was negative $18.9 million for the third quarter of 2026.

Guidance

  • Estimated total revenue of approximately $124 million to $126 million for the full year 2026.
  • Estimated 37% to 39% of new patient starts reimbursed through the PBP channel.
  • Estimated gross margin of 58.5% to 59.5%.

Notes

Quality system remediation expenses were previously labeled ‘Other non-recurring’ in the Form 10-K for the year ended December 31, 2025.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-27 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →